Artelo Biosciences (NASDAQ:ARTL – Get Free Report) is projected to issue its Q3 2026 results before the market opens on Tuesday, November 17th. Analysts expect Artelo Biosciences to post earnings of ($7.02) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.
Artelo Biosciences (NASDAQ:ARTL – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.48) by $5.59.
Artelo Biosciences Stock Up 8.4%
Shares of Artelo Biosciences stock opened at $2.07 on Tuesday. The business’s 50 day simple moving average is $3.80 and its two-hundred day simple moving average is $20.62. Artelo Biosciences has a one year low of $1.91 and a one year high of $179.19.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Artelo Biosciences in a research note on Monday, September 21st. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce”.
View Our Latest Analysis on Artelo Biosciences
About Artelo Biosciences
Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that target the endocannabinoid system, a biological signaling network involved in areas such as pain, appetite, inflammation and cancer. The company’s programs are designed to address unmet medical needs in oncology and other therapeutic areas.
Artelo’s development pipeline has included ART27.13, a peripherally restricted cannabinoid receptor type 1 agonist being investigated for cancer-related anorexia and cachexia.
Further Reading
- Five stocks we like better than Artelo Biosciences
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
